Review of CPHI 2025
19. November 2025
IOI Oleo GmbH demonstrates its strength as an Innovation Partner to the pharmaceutical industry. CPHI 2025 in Frankfurt was an outstanding success for IOI Oleo GmbH – a strong statement of innovation, customer focus, and collaborative partnership.
The event kicked off with the Partner Summit on October 27, 2025, which offered leading industry partners exclusive insights into current developments and strategic initiatives. The highlight of the summit was the premiere of the new LipoGalen™ product line, designed to meet the evolving needs of modern pharmaceutical formulations. In addition, IOI Oleo presented new application possibilities for the proven emulsifier IMWITOR® 375 and showcased expanded R&D capabilities for the synthesis of high-purity pharmaceutical actives and excipients.
Under the guiding themes “Lipids without Limits” and “Formulate the Future,” IOI Oleo set clear impulses for the future of lipid-based formulations at CPHI from October 28–30. The launch of LipoGalen™ formed the centrepiece of the company’s trade fair presence and attracted strong interest from the international professional audience. Of particular note was LipoGalen™ 144, which impressed as a versatile matrix material for ovules and suppositories. The accompanying case study on lactic acid ovules provided valuable first-hand insights into practical applications.
Another key focus was the broad range of applications for IMWITOR® 375, especially in improving the bioavailability of poorly soluble actives and optimizing skin permeation in topical formulations. With these innovations, IOI Oleo once again demonstrated its expertise in developing lipid-based Advanced Delivery Systems for the pharmaceutical and Nutraceutical industries.
With a modern, open booth design and a targeted communication strategy, IOI Oleo succeeded in presenting complex technical topics in a clear, engaging, and brand-consistent way. This resulted in strong visitor interest, intensive customer dialogue, and consistently positive feedback from customers, distributors, and industry partners.
Outstanding team performance, expertise, creativity and commitment: At CPHI 2025, our team once again showed that IOI Oleo GmbH, a leading and reliable partner supplier of lipid-based excipients, is a strategic partner for companies that count on innovation, quality and mutual cooperation in pharmaceutical development.
Dr. Thomas Rillmann
Dr. Thomas Rillmann studied Chemistry at the Technical University of Munich and Pharmacy at the Technical University of Braunschweig, finishing his Ph.D. thesis under the supervision of Prof. Dr. Dr. h.c. Claus Führer. He has more than 25 years of experience in the pharmaceutical industry, mainly working in product development and transfer. He started his professional career at Hexal Pharmaforschung GmbH working on multi-particulate controlled release dosage forms, then joining the STADA group, building up the Pharmaceutical Development Department from 2003 to 2010 and the Product Transfer Department from 2008 to 2009. After a 4-year’s stint in the pharma business segment of BASF SE, he held to two positions in pharmaceutical manufacturing, the last position as a Site Head for Riemser Pharma GmbH. Thomas Rillmann joined IOI Oleo GmbH on January 1st 2023 as Head of Business Development Functional Excipients.
